Company intelligence / Profile preview

Honso Pharmaceutical

Lianyungang, Jiangsu, China

Ownership: Private
Employees: ~1900
Development stage: Other

Overview

Hansoh has 7 innovative drugs approved for 9 indications in China, with strong efficacy and safety demonstrated in leading clinical trials (e.g., Ameile (aumolertinib) in NSCLC), and an extensive clinical-stage pipeline in key therapeutic areas

Therapeutic areas: Women's HealthInfectious DiseasesNeurologyMetabolic DisordersDermatologyOncology
Modalities: Small moleculePeptidesBiologicAntibody-drug conjugateMonoclonal antibodyBispecific monoclonal antibodysiRNAFusion proteinPROTACNanoformulationPEGylated biologic
Industry: Biotech

Partnerships

GSK (HS-20093, HS-20089 global licensing)RegeneronMSD

Beyond the preview

Go deeper on Honso Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Honso Pharmaceutical.

Explore the full profile